Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have earned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $6.67.

A number of analysts recently commented on IPHA shares. Leerink Partners raised Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Tuesday, August 11th. BTIG Research reiterated a “buy” rating and issued a $9.00 price target on shares of Innate Pharma in a report on Thursday, September 17th. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. HC Wainwright restated a “buy” rating on shares of Innate Pharma in a report on Monday, September 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Innate Pharma in a report on Tuesday, September 22nd.

Innate Pharma Price Performance

IPHA opened at $1.50 on Friday. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.71. The stock’s 50 day moving average price is $1.83 and its 200-day moving average price is $1.77.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company researches treatments designed to activate or enhance the immune system’s ability to recognize and eliminate tumor cells, with an emphasis on natural killer cells and other components of the innate immune system.

Its pipeline includes lacutamab, an antibody directed at KIR3DL2 that is being studied in certain forms of cutaneous T-cell lymphoma. Innate Pharma has also developed monalizumab, an antibody targeting the NKG2A immune checkpoint, through a collaboration with AstraZeneca.